Literature DB >> 35105494

Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

S Kristen Sexson Tejtel1, Flor M Munoz2, Iyad Al-Ammouri3, Fabio Savorgnan4, Rama K Guggilla5, Najwa Khuri-Bulos6, Lee Phillips7, Renata J M Engler8.   

Abstract

Myocarditis and/or pericarditis (also known as myopericarditis) are inflammatory diseases involving the myocardium (with non-ischemic myocyte necrosis) and/or the pericardial sac. Myocarditis/pericarditis (MPC) may present with variable clinical signs, symptoms, etiologies and outcomes, including acute heart failure, sudden death, and chronic dilated cardiomyopathy. Possible undiagnosed and/or subclinical acute myocarditis, with undefined potential for delayed manifestations, presents further challenges for diagnosing an acute disease and may go undetected in the setting of infection as well as adverse drug/vaccine reactions. The most common causes of MPC are viral, with non-infectious, drug/vaccine associated hypersensitivity and/or autoimmune causes being less well defined and with potentially different inflammatory mechanisms and treatment responses. Potential cardiac adverse events following immunization (AEFIs) encompass a larger scope of diagnoses such as triggering or exacerbating ischemic cardiac events, cardiomyopathy with potential heart failure, arrhythmias and sudden death. The current published experience does not support a potential causal association with vaccines based on epidemiologic evidence of relative risk increases compared with background unvaccinated incidence. The only evidence supporting a possible causal association of MPC with a vaccine comes from case reports. Hypersensitivity MPC as a drug/vaccine induced cardiac adverse event has long been a concern for post-licensure safety surveillance, as well as safety data submission for licensure. Other cardiac adverse events, such as dilated cardiomyopathy, were also defined in the CDC definitions for adverse events after smallpox vaccination in 2006. In addition, several groups have attempted to develop and improve the definition and adjudication of post-vaccination cardiovascular events. We developed the current case definitions for myocarditis and pericarditis as an AEFI building on experience and lessons learnt, as well as a comprehensive literature review. Considerations of other etiologies and causal relationships are outside the scope of this document.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Adverse events; Brighton Collaboration; Case definition; Guidelines; Immunization; Myocarditis; Myopericarditis; Pericarditis

Mesh:

Year:  2022        PMID: 35105494     DOI: 10.1016/j.vaccine.2021.11.074

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12-17-year olds in Victoria, Australia.

Authors:  Daryl R Cheng; Hazel J Clothier; Hannah J Morgan; Emma Roney; Priya Shenton; Nicholas Cox; Bryn O Jones; Silja Schrader; Nigel W Crawford; Jim P Buttery
Journal:  BMJ Paediatr Open       Date:  2022-06

2.  A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).

Authors:  Brett Leav; Walter Straus; Phil White; Alison Leav; Tashawnee Gaines; Grace Maggiacomo; Denny Kim; Emily R Smith; Marc Gurwith; Robert T Chen
Journal:  Vaccine       Date:  2022-06-09       Impact factor: 4.169

3.  Myocarditis Following the Second Dose of COVID-19 Vaccination in a Japanese Adolescent.

Authors:  Shohei Yamamoto; Yoh Arita; Nobuyuki Ogasawara
Journal:  Cureus       Date:  2022-03-25

4.  Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.

Authors:  Sarah A Buchan; Chi Yon Seo; Caitlin Johnson; Sarah Alley; Jeffrey C Kwong; Sharifa Nasreen; Andrew Calzavara; Diane Lu; Tara M Harris; Kelly Yu; Sarah E Wilson
Journal:  JAMA Netw Open       Date:  2022-06-01

Review 5.  COVID-19 review shows that benefits of vaccinating children and adolescents appear to outweigh risks of post-vaccination myopericarditis.

Authors:  Rosa Morello; Mara Pepe; Laura Martino; Ilaria Lazzareschi; Antonio Chiaretti; Antonio Gatto; Antonietta Curatola
Journal:  Acta Paediatr       Date:  2022-07-08       Impact factor: 4.056

Review 6.  Global reports of takotsubo (stress) cardiomyopathy following COVID-19 vaccination: A systematic review and meta-analysis.

Authors:  Sirwan Khalid Ahmed; Mona Gamal Mohamed; Rawand Abdulrahman Essa; Eman Abdelaziz Ahmed Rashad Dabou; Salar Omar Abdulqadir; Rukhsar Muhammad Omar
Journal:  Int J Cardiol Heart Vasc       Date:  2022-08-17

7.  Case report: Five patients with myocarditis after mRNA COVID-19 vaccination.

Authors:  Hiroki Murase; Yiqing Zhu; Keiya Sakaida; Hayato Mizuno; Hiromitsu Mori; Hideyuki Iwayama; Noriyuki Suzuki; Noriko Nagai; Akihisa Okumura
Journal:  Front Pediatr       Date:  2022-08-18       Impact factor: 3.569

8.  A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons.

Authors:  Nir Levi; Gil Moravsky; Yonit Wiener-Well; Tal Hasin; Tatyana Weitsman; Itshak Amsalem; Sarit Bar-Sheshet Itach; Nurit Algur; Ira Lapidus; Ofir Mitz; Michael Glikson
Journal:  Eur J Heart Fail       Date:  2022-09-13       Impact factor: 17.349

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.